'''Roxindole''' ('''EMD-49,980''') is a [[dopaminergic]] and [[serotonergic]] [[drug]] which was originally developed for the treatment of [[schizophrenia]].<ref name="pmid7870927">{{cite journal |vauthors=Gründer G, Wetzel H, Hammes E, Benkert O | title = Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression | journal = Psychopharmacology | volume = 111 | issue = 1 | pages = 123–6 | year = 1993 | pmid = 7870927 | doi = 10.1007/BF02257418| url = }}</ref><ref name="pmid1684439">{{cite journal |vauthors=Klimke A, Klieser E | title = Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study | journal = Pharmacopsychiatry | volume = 24 | issue = 4 | pages = 107–12 |date=July 1991 | pmid = 1684439 | doi = 10.1055/s-2007-1014451| url = }}</ref><ref name="pmid1353388">{{cite journal |vauthors=Kasper S, Fuger J, Zinner HJ, Bäuml J, Möller HJ | title = Early clinical results with the neuroleptic roxindole (EMD 49,980) in the treatment of schizophrenia--an open study | journal = European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology | volume = 2 | issue = 1 | pages = 91–5 |date=March 1992 | pmid = 1353388 | doi = 10.1016/0924-977X(92)90041-6| url = http://linkinghub.elsevier.com/retrieve/pii/0924-977X(92)90041-6}}</ref> In [[clinical trial]]s its [[antipsychotic]] efficacy was only modest but it was unexpectedly found to produce potent and rapid [[antidepressant]] and [[anxiolytic]] effects.<ref name="pmid1684439"/><ref name="pmid1353388"/> As a result, roxindole was further researched for the treatment of [[major depression|depression]] instead.<ref name="pmid7870927"/><ref name="pmid8811507">{{cite journal |vauthors=Maj J, Kolodziejczyk K, Rogóz Z, Skuza G | title = Roxindole, a potential antidepressant. I. Effect on the dopamine system | journal = Journal of Neural Transmission (Vienna, Austria : 1996) | volume = 103 | issue = 5 | pages = 627–41 | year = 1996 | pmid = 8811507 | doi = 10.1007/bf01273159| url = }}</ref><ref name="pmid8811507"/> It has also been investigated as a therapy for [[Parkinson's disease]] and [[prolactinoma]].<ref name="pmid8097280">{{cite journal |vauthors=Bravi D, Davis TL, Mouradian MM, Chase TN | title = Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980 | journal = Movement Disorders : Official Journal of the Movement Disorder Society | volume = 8 | issue = 2 | pages = 195–7 |date=April 1993 | pmid = 8097280 | doi = 10.1002/mds.870080214 | url = }}</ref><ref name="pmid7950157">{{cite journal |vauthors=Jaspers C, Benker G, Reinwein D | title = Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results | journal = The Clinical Investigator | volume = 72 | issue = 6 | pages = 451–6 |date=June 1994 | pmid = 7950157 | doi = 10.1007/bf00180520| url = }}</ref>

 
At D<sub>2</sub> and possibly D<sub>3</sub> receptors roxindole is a [[partial agonist]] with preferential actions at [[autoreceptor]]s and has been touted as a '[[binding selectivity|selective]]' autoreceptor agonist, hence the justification of its application as an antipsychotic.<ref name="pmid2565817">{{cite journal |vauthors=Seyfried CA, Greiner HE, Haase AF | title = Biochemical and functional studies on EMD 49,980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems | journal = European Journal of Pharmacology | volume = 160 | issue = 1 | pages = 31–41 |date=January 1989 | pmid = 2565817 | doi = 10.1016/0014-2999(89)90651-1| url = http://linkinghub.elsevier.com/retrieve/pii/0014-2999(89)90651-1}}</ref><ref name="pmid8558454">{{cite journal |vauthors=Bartoszyk GD, Harting J, Minck KO | title = Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 276 | issue = 1 | pages = 41–8 |date=January 1996 | pmid = 8558454 | doi = | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=8558454}}</ref> Weaker activity at the serotonin 1<sub>B</sub> and 1<sub>D</sub> receptors has been seen.<ref>{{Cite journal|title = Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors|journal = Naunyn-Schmiedeberg's Archives of Pharmacology|date = Jun 1999|issn = 0028-1298|pmid = 10431754|pages = 447–453|volume = 359|issue = 6|first = A.|last = Newman-Tancredi|first2 = D.|last2 = Cussac|first3 = V.|last3 = Audinot|first4 = M. J.|last4 = Millan|doi=10.1007/pl00005374}}</ref> It is also a [[serotonin reuptake inhibitor]] (IC<sub>50</sub> = 1.4 nM) and has been reported to act as a [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] [[receptor antagonist|antagonist]] as well.<ref name="pmid15341483"/><ref name="pmid2565817"/><ref name="pmid8558454"/><ref name="pmid9131725">{{cite journal |vauthors=Maj J, Kołodziejczyk K, Rogóz Z, Skuza G | title = Roxindole, a dopamine autoreceptor agonist with a potential antidepressant activity. II. Effects on the 5-hydroxytryptamine system | journal = Pharmacopsychiatry | volume = 30 | issue = 2 | pages = 55–61 |date=March 1997 | pmid = 9131725 | doi = 10.1055/s-2007-979483| url = }}</ref>
